Informuta, Inc. — SEC Form D Filing

Informuta, Inc. filed an SEC Form D on November 5, 2026, reporting $713K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
November 5, 2026
Amount reported
$713K
Round stage
Seed
Industry
Biotechnology
Website
https://www.informuta.com

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Existing diagnostic tools for antimicrobial resistance are reactive and backward-looking, leaving clinicians without tests to forecast if a pathogen will develop resistance to selected treatments.

Solution

Informuta provides a predictive infection intelligence platform that maps whole-genome mutational signatures using AI to detect existing resistance patterns and forecast treatment-emergent resistance risk.

Why now

Rising antimicrobial resistance rates globally and the dropping cost of rapid pathogen whole-genome sequencing make predictive AI-driven resistance modeling feasible in clinical timelines.

Verdict

Informuta cleared an initial tranche because the predictive mutation thesis offered an intellectually seductive escape from brutal rapid-phenotypic diagnostics competition, not because hospital microbiology labs possess an identifiable budget to buy standalone predictive software. Investors were implicitly betting that sequencing costs and turnaround times would collapse fast enough to make prospective genomic forecasting clinically actionable before standard culture results return. The micro-scale $713k round reflects capped conviction, driven by standard hospital sales friction and the unresolved question of who actually pays for predictive insights under fixed inpatient reimbursement bundles.

Source: SEC EDGAR Form D filing